US 12,460,266 B2
Kit, device, and method for detecting lung cancer
Yuho Kida, Kamakura (JP); Satoko Kozono, Kamakura (JP); Hiroko Sudo, Kamakura (JP); Satoshi Kondou, Kamakura (JP); Junpei Kawauchi, Kamakura (JP); Takahiro Ochiya, Tokyo (JP); and Shun-ichi Watanabe, Tokyo (JP)
Assigned to TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed by TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed on Jun. 11, 2024, as Appl. No. 18/739,680.
Application 18/739,680 is a division of application No. 18/120,059, filed on Mar. 10, 2023, granted, now 12,043,872.
Application 18/120,059 is a division of application No. 16/626,781, granted, now 11,634,778, issued on Apr. 25, 2023, previously published as PCT/JP2018/024834, filed on Jun. 29, 2018.
Claims priority of application No. 2017-126933 (JP), filed on Jun. 29, 2017.
Prior Publication US 2024/0344146 A1, Oct. 17, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/6816 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 1/6816 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/7028 (2013.01)] 7 Claims
 
1. A method for detecting and treating or performing a diagnostic procedure for lung cancer, comprising: determining an expression level of hsa-miR-3619-3p in a sample from a human subject using a nucleic acid(s) capable of specifically binding to hsa-miR-3619-3p, or using a kit or device comprising a nucleic acid(s) capable of specifically binding to
hsa-miR-3619-3p,
wherein the determining comprises the following steps of:
(a) isolating a sample from a human subject comprising hsa-miR-3619-3p;
(b) contacting hsa-miR-3619-3p in the sample or complementary polynucleotide(s) thereof prepared from hsa-miR-3619-3p with the nucleic acid(s);
(c) measuring an expression level of hsa-miR-3619-3p;
(d) comparing the expression level of hsa-miR-3619-3p measured in the step (c) to a control expression level of hsa-miR-3619-3p in a control sample from a healthy human subject measured in the same way as in the step (c) to allow for diagnosis of lung cancer;
(e) detecting a increased level of hsa-miR-3619-3p in the sample from the human subject as compared to the control expression level of hsa-miR-3619-3p from the sample from the human subject that does not have lung cancer, wherein the increased level of hsa-miR-3619-3p indicates that the human subject has lung cancer; and
(f) treating the human subject having lung cancer or performing a diagnostic procedure on the human subject having lung cancer;
wherein the sample is blood, serum, or plasma;
wherein the treatment comprises chemotherapy, radiotherapy, immunotherapy, molecular targeted therapy, surgery or a combination thereof; and
wherein the diagnostic procedure comprises an imaging test method selected from the group consisting of a chest X-ray examination, CT examination, MRI examination, and PET examination; a pathological examination method selected from the group consisting of sputum cytology, pleural fluid analysis, bronchoscopy, and percutaneous needle biopsy; or a combination thereof.